<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3227">
  <stage>Registered</stage>
  <submitdate>7/07/2011</submitdate>
  <approvaldate>7/07/2011</approvaldate>
  <nctid>NCT01392196</nctid>
  <trial_identification>
    <studytitle>Renal Denervation in Patients With Chronic Heart Failure &amp; Renal Impairment Clinical Trial</studytitle>
    <scientifictitle>Renal Denervation in Patients With Chronic Heart Failure &amp; Renal Impairment</scientifictitle>
    <utrn />
    <trialacronym>SymplicityHF</trialacronym>
    <secondaryid>TP085</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: surgery - Renal Denervation

Other: Single arm - Renal Denervation


Treatment: surgery: Renal Denervation
Renal Denervation using the Symplicity Catheter in Heart Failure Population

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety of Renal Denervation in Heart Failure patients as measured by Adverse Events</outcome>
      <timepoint>6 month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Ventricular function as measured by Echocardiography</outcome>
      <timepoint>6 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Renal function as measured by Glomerular Filtration Rate (GFR)</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Heart Failure patients NYHA Class II or III

          -  Renal Impairment Left Ventricular Ejection Function &lt;40%

          -  GFR 30 to 75 mL/min/1.73m2

          -  Optimal stable medical therapy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Renal artery anatomy must be eligible for treatment as determined by Angiography, and

          -  History of prior renal artery intervention

          -  Single functioning kidney.

          -  Myocardial Infarction, unstable angina pectoris or cerebrovascular Accident within 3
             months

          -  Systolic BP &lt; 90 mmHG</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>39</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Alfred Hospital - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medtronic Vascular</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a feasibility study enrolling up to 40 patients in Australia and Europe. The primary
      aim of the study is to demonstrate the renal denervation with the Symplicity Catheter is safe
      and determine the evidence of a response to renal denervation in patients with Heart Failure.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01392196</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Henry Krum, MD</name>
      <address>The Alfred</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>